Key Segmentation
By Phage / Product Type
-
dsDNA Bacteriophage
-
ssDNA Bacteriophage
-
ssRNA Bacteriophage
-
Phage Cocktails / Engineered Preparations
-
Delivery / Formulation Types
By Administration / Route
-
Oral
-
Topical / External Application
-
Injectable / Surgical Administration
By Application / Use Case
-
Human Therapeutics
-
Veterinary Medicine
-
Agriculture & Crop Protection
-
Aquaculture
-
Food Safety & Preservation
-
Research & Development / Diagnostics
By End-User / Customer Type
-
Hospitals & Clinics
-
Pharmaceutical & Biotechnology Companies
-
Research & Academic Institutions
-
Veterinary Care Providers
-
Food & Beverage / Processing Industry
-
Agricultural Enterprises
By Target Bacterial Indication / Disease
-
Urinary Tract Infections
-
Wound & Skin Infections
-
Respiratory Infections
-
Bone & Orthopedic Infections
-
Chronic Conditions
-
Other Pathogen-Specific Indications
Request for Segment Customization as per your Business Requirement:
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The Phage Therapy Market is projected to grow at a CAGR of 3.91% during 2026–2035.
The market is valued at USD 1.27 Billion in 2025 and is projected to reach USD 1.86 Billion by 2035.
Growth is driven by rising antibiotic resistance, wider adoption of phage therapies, advanced phage engineering, and expanding human, veterinary, and agricultural applications.
By Phage / Product Type, dsDNA Bacteriophage dominated with a 38.45% share, while Phage Cocktails / Engineered Preparations are projected to grow at the fastest CAGR of 5.42% during 2026–2035.
North America dominated with a 41.87% share in 2025, while Asia-Pacific is the fastest-growing region, projected to expand at a CAGR of 5.29% during 2026–2035.